Wen-Lian Wu

This inventor holds 37 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 20 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Merck Sharp + Dohme Corp., Schering Corporation, Angex Pharmaceutical, Inc.. Active years: 2003-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wen-Lian Wu. Retrieved from https://idiyas.com/inventor/wen-lian-wu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 2)

% Patents Active = 62.2

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 20 (Patent Applications = 22)

Average Co-Inventor Count = 4.3

ph-index = 5

Forward Citations = 82(Granted Patents)

Location History:

Edison, NJ (US) (2003 - 2016)
Green Brook, NJ (US) (2017 - 2023)

Company Filing History:

20 out of 2,405

Merck Sharp + Dohme Corp.

Angex Pharmaceutical, Inc.

patents

Years Active: 2003-2023

Loading Chart...

Areas of Expertise:

BACE Inhibitors

Gamma Secretase Inhibitors

MCH Receptor Antagonists

Cyclic Compounds

Tricyclic Heterocycles

Immunomodulating Agents

Multikinase Inhibitors

Dipeptidyl Peptidase-IV Inhibitors

Diabetes Treatment

Cardiometabolic Disease

Obesity Treatment

Therapeutic Agents

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11685761 - Cyclic di-nucleotide compounds as sting agonists (2023-06-27),

2. 11466047 - Cyclic di-nucleotide compounds as sting agonists (2022-10-11),

3. 11358949 - Carbamate and urea compounds as multikinase inhibitors (2022-06-14),

4. 11180497 - Cyclic compounds as immunomodulating agents (2021-11-23),

5. 11098046 - Macrocyclic compounds as TRK kinase inhibitors and uses thereof (2021-08-24),

6. 11008338 - C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use (2021-05-18),

7. 10689401 - C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use (2020-06-23),

8. 10414775 - Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease (2019-09-17),

9. 10414774 - Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease (2019-09-17),

10. 10071998 - Iminothiadiazine dioxides bearing an amine-linked substituent as BACE inhibitors, compositions, and their use (2018-09-11),

11. 9732088 - C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use (2017-08-15),

12. 9725468 - C5-spiro iminothiazine dioxides as BACE inhibitors, compositions, and their use (2017-08-08),

13. 9499502 - 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use (2016-11-22),

14. 9453034 - C2-azaspiro iminothiazine dioxides as BACE inhibitors, compositions, and their use (2016-09-27),

15. 9365589 - C5, C6 oxacyclic-fused thiazine dioxide compounds as BACE inhibitors, compositions, and their use (2016-06-14),

As a specialist in innovations, inventions, inventors, patent attorneys, assignees, and patents, I focus primarily on providing information related to these specific topics. If you require assistance outside of this scope, please let me know so I can better assist you.

Profile summary based on public USPTO records.